黑料网

Biography

Dr. Fang is a Research Biologist at the Division of Biochemical Toxicology, National Center for Toxicological Research/FDA. Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has been the principal investigator on many approved NCTR protocols that address the biological mechanisms underlying the toxicities of drugs and chemicals. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.

Dr. Fang received a Bachelor’s degree in Public Health in 1985 from Shanghai Medical University and a Master’s degree in Toxicology in 1990 from Chinese Academy of Preventive Medicine in China. In 1997, Dr. Fang received his Ph.D. in Molecular Epidemiology from the renowned Karolinska Institute in Stockholm, Sweden. He joined the NCTR/FDA as an ORISE Postdoctoral Fellow in 1997 and rejoined the NCTR/FDA as a Staff Fellow in 2004. Dr. Fang is author/co-author of 56 publications including peer-reviewed articles and/or scientific reports.

Research Interest

Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has designed, developed, and executed in vitro and in vivo research investigations that address the biological mechanisms underlying the toxicities of drugs and chemicals. Throughout his career at NCTR, Dr. Fang’s research has been focused on the biological mechanisms of action underlying the toxicity of chemicals regulated by, or of interest to, the FDA, such as ethanol, urethane, tolvaptan, and antiretroviral drugs, including zidovudine, lamivudine, and nevirapine. More recently, Dr. Fang has been leading a research team to investigate the toxicities of topically applied triclosan. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.